Related Experiment Video

Updated: Apr 18, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?

Robert Pirker

    Future Oncology (London, England)
    |January 10, 2015
    PubMed

    Insights

    Epidermal Growth Factor Receptor (EGFR) targeted therapies, including tyrosine kinase inhibitors and antibodies, show promise in treating non-small-cell lung cancer by blocking EGFR signaling and improving patient survival.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Pharmacology

    Background:

    • Epidermal Growth Factor Receptor (EGFR) overexpression/activation is common in non-small-cell lung cancer (NSCLC).
    • EGFR signaling pathways are critical in NSCLC proliferation and survival.
    • Targeting EGFR represents a key therapeutic strategy for NSCLC.

    Purpose of the Study:

    • To summarize clinical data on Epidermal Growth Factor Receptor (EGFR) targeted therapies for non-small-cell lung cancer.
    • To review the efficacy of EGFR tyrosine kinase inhibitors (TKIs) and anti-EGFR antibodies.
    • To discuss the role of investigational multikinase TKIs.

    Main Methods:

    • Review of available clinical trial data for EGFR-targeted therapies.
    • Analysis of efficacy and safety profiles of approved and investigational agents.
    • Synthesis of information on monotherapy and combination treatment strategies.

    Main Results:

    • Three EGFR-TKIs are approved for initial monotherapy in patients with EGFR-activating mutations.
    • Erlotinib is established for maintenance and second-line therapy.
    • Investigational anti-EGFR antibodies combined with standard therapy improve survival in advanced NSCLC, particularly in high EGFR-expressing tumors.

    Conclusions:

    • EGFR-targeted therapies, including TKIs and antibodies, are effective in NSCLC treatment.
    • Combination strategies with anti-EGFR antibodies show survival benefits.
    • Ongoing research into multikinase TKIs may offer further treatment options.
    Keywords:
    EGFRadvanced lung cancermonoclonal antibodiestargeted therapytyrosine kinase inhibitors

    More Related Videos

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    9.3K
    Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

    Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

    Published on: October 10, 2025

    552

    Related Concept Videos

    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    8.5K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.2K
    Transducer Mechanism: Enzyme-Linked Receptors01:27

    Transducer Mechanism: Enzyme-Linked Receptors

    Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
    Major types that are helpful drug targets include:
    5.1K
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    72